双介入联合CIK细胞治疗中晚期肝细胞肝癌

Transcatheter hepatic arterial chemoembolization and percutaneous ethanol injection combined with cytokine-induced killer cells in treatment of advanced hepatocellular carcinoma

目的:评估双介入联合细胞因子诱导的杀伤细胞(CJK细胞) 过继免疫治疗中晚期肝细胞肝癌的临床疗效. 方法:采用经皮肝动脉栓塞化疗术(TACE)、经皮肝瘤体内注入无水乙醇术(PEI)、CIK细胞回输3种方法治疗中晚期肝细胞肝癌共128例,其中在TACE、PEI双介入的基础上,采用CIK细胞静脉回输与瘤体内注射相结合治疗中晚期肝细胞肝癌36例(研究组),并与同期病情相当的中晚期肝细胞肝癌双介入治疗62例(双介入组)和单纯的TACE30 例(单纯组)相比较. 结果:研究组、双介入组、单纯组有效率分别为91.6%、75.8%和43.3%,研究组的AFP下降、细胞免疫功能、卡氏评分升高均优于双介入组和单纯组,研究组的1 a生存也得到显著的延长(P<0.05). 结论:双介入治疗联合CIK细胞可以弥补单一治疗方法的不足,增强了抗癌效果,改善了患者的生存质量,延长了患者的生存期.

AIM: To evaluate the clinical effects of double intervention combined with the adoptive immunotherapy with cytokine-induced killer (CIK) cells on advanced hepatocellular carcinoma (HCC). METHODS: A total of 128 patients with advanced HCC were treated by transcatheter hepatic arterial chemoembolization (TACE) and/or percutaneous ethanol injection (PEI) and/ or CIK cells. Another 36 patients with HCC were treated by TACE and PEI combined with CIK cells (study group). They were compared with either 62 patients with HCC treated by TACE and PEI (double intervention group) or 30 patients with HCC treated by TACE (simple group). RESULTS: The effective rate of the study group, double intervention group and simple group were 91.6%, 75.8% and 43.3% respectively. The immune function, the Karnofsky''s grade, 1 year survival in the study group were significantly higher than those in the double intervention group and simple group. But serum AFP in the study group was lower than that in the others (P<0.05). CONCLUSION: TACE and PEI combined with CIK cells enhances the anti-cancer effect, improve the survival quantity and prolong survival period of the patients.